Metycor

Active substance

Metyparone

Holder

Laboratoires HRA Pharma

Status

Running

Indication

Endogenous Cushing’s syndrome in patients who have completed the study extension period of the PROMPT clinical trial with metyrapone

Public documents

Approbation

Information for the patient

Informed consent

Last update

18/05/2016

Last updated on 13/04/2021